<p><strong>资深生物科技首席财务官带来超过 20 年的上市公司财务领导和 IPO 经验，以支持 Genvor 的双市场增长战略</strong></p>
<p>加利福尼亚州伍德兰，2026 年 5 月 21 日（全球新闻稿）——Genvor, Inc.（OTCQB: GNVR）（“Genvor”）是一家利用人工智能生成新型肽的生物科技公司，提供高性能解决方案，涵盖农业和人类健康，今天宣布任命 Donald Kalkofen 为首席财务官。在此角色中，Kalkofen 先生将领导 Genvor 的财务战略，推动公司在农业和人类健康与福祉领域的双市场商业化计划。</p>
<p>Kalkofen 先生拥有超过 20 年的首席财务官经验，曾在生物科技、金融服务和技术领域领导财务和运营，拥有指导公司完成首次公开募股和复杂资本市场交易的成功记录。最近，他担任 Alpha Cognition, Inc.的首席财务官，这是一家专注于中枢神经系统的上市生物科技公司，致力于为患有神经退行性疾病（如阿尔茨海默病）的患者开发治疗方案，他领导了公司成功上市纳斯达克的准备工作，并帮助建立新的银行、审计委员会和投资者关系职能。在加入 Alpha Cognition 之前，Kalkofen 先生曾担任 Protagonist Therapeutics 的首席财务官，这是一家上市的临床阶段生物制药公司，他帮助指导公司实现强劲增长，并支持公司成功实施 SOX 404(b)。在职业生涯早期，Kalkofen 先生在 Symantec Corporation 和 West Coast Bancorp 担任首席财务官和高级财务领导职务，他在纳斯达克成功上市并将银行资产从 9000 万美元增长到 15 亿美元。</p>
<p>“Don 在指导生物科技公司经历转型增长方面的记录使他成为 Genvor 在这一发展阶段的理想财务领导，” Genvor 首席执行官 Chad Pawlak 表示。“他深厚的上市公司经验，加上对复杂资本市场和合作交易的掌控，使他能够支持未来在农业和人类健康与福祉平台上结构化的联合开发协议。”</p>
<p>“Genvor 正处于一个激动人心的转折点，拥有专有的肽平台、不断扩展的产品线，以及在两个互补市场上清晰的增长路径，” Kalkofen 先生表示。“我曾帮助生物科技公司经历类似的转型，期待与 Chad 和团队一起工作，强化 Genvor 的财务基础，推动公司的下一个增长阶段。”</p>
<p>Kalkofen 先生是一名注册会计师（非活跃），并持有华盛顿州立大学的会计学学士学位。</p>
<p><strong>关于 Genvor</strong></p>
<p>Genvor, Inc.（OTCQB: GNVR）是一家利用人工智能生成新型肽的生物科技公司，提供高性能解决方案，涵盖农业和人类健康。Genvor 依托其专有的 BioCypher™平台和专利肽，正在开发并打算商业化用于作物保护和植物健康的生物活性物质，以及面向消费者的肽解决方案，涵盖恢复、性能、抗衰老和日常健康。通过其技术平台和未来的合作伙伴关系，Genvor 旨在推动自然、基于科学的创新新时代。欲了解更多信息，请访问 www.genvor.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中关于未来期望、计划和前景的声明，以及任何其他关于非历史事实事项的声明，可能构成 “前瞻性声明”。这些声明包括但不限于与公司运营相关的声明。词语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 和类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。本新闻稿中包含的前瞻性声明基于管理层当前的预期，并受到重大风险、不确定性和情况变化的影响。实际结果可能与这些前瞻性声明所指示的结果有实质性差异，原因包括但不限于市场条件等各种重要因素。所有这些声明仅在本新闻稿日期时有效。因此，前瞻性声明应仅被视为 Genvor 当前的计划、估计和信念。Genvor 无法保证未来的结果、事件、活动水平、表现或成就。Genvor 不承担并特别拒绝任何更新或修订前瞻性声明的义务，以反映新信息、未来事件或情况，或反映意外事件的发生，除非适用法律要求。</p>
<p><strong>联系方式：</strong> Carly Scaduto</p>
<p>carly@carlyscadutoconsulting.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU5ETTJOaU0zTmpFME9UQTVJelV3TURFMU16RXdNUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU5ETTJOaU0zTmpFME9UQTVJelV3TURFMU16RXdNUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDk2Nzc0ODktYzM4Zi00NGMzLTllMWItNDRiMGVhMDM5OTY4LTUwMDE1MzEwMS0yMDI2LTA1LTIxLWVu/tiny/Genvor-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDk2Nzc0ODktYzM4Zi00NGMzLTllMWItNDRiMGVhMDM5OTY4LTUwMDE1MzEwMS0yMDI2LTA1LTIxLWVu/tiny/Genvor-Inc.png"/></p>

Protagonist治疗

ACOG

医疗业 ETF - SPDR

<p>Genvor, Inc. 任命 Donald Kalkofen 为首席财务官，以领导其财务战略，推动公司在农业和人类健康市场的增长。Kalkofen 拥有超过 20 年的上市公司财务经验，包括成功的首次公开募股。他曾担任 Alpha Cognition 和 Protagonist Therapeutics 的首席财务官，指导这两家公司经历显著增长和上市。Genvor 旨在利用他的专业知识来加强其财务基础，并推进其双市场商业化计划</p>

<p><strong>Seasoned biotech CFO brings 20+ years of public company finance leadership and IPO experience to support Genvor’s dual-market growth strategy</strong></p>
<div class="lb-trans"><p><strong>资深生物科技首席财务官带来超过 20 年的上市公司财务领导和 IPO 经验，以支持 Genvor 的双市场增长战略</strong></p>
</div><p>Woodland, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health, today announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness.</p>
<div class="lb-trans"><p>加利福尼亚州伍德兰，2026 年 5 月 21 日（全球新闻稿）——Genvor, Inc.（OTCQB: GNVR）（“Genvor”）是一家利用人工智能生成新型肽的生物科技公司，提供高性能解决方案，涵盖农业和人类健康，今天宣布任命 Donald Kalkofen 为首席财务官。在此角色中，Kalkofen 先生将领导 Genvor 的财务战略，推动公司在农业和人类健康与福祉领域的双市场商业化计划。</p>
</div><p>Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition, Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets.</p>
<div class="lb-trans"><p>Kalkofen 先生拥有超过 20 年的首席财务官经验，曾在生物科技、金融服务和技术领域领导财务和运营，拥有指导公司完成首次公开募股和复杂资本市场交易的成功记录。最近，他担任 Alpha Cognition, Inc.的首席财务官，这是一家专注于中枢神经系统的上市生物科技公司，致力于为患有神经退行性疾病（如阿尔茨海默病）的患者开发治疗方案，他领导了公司成功上市纳斯达克的准备工作，并帮助建立新的银行、审计委员会和投资者关系职能。在加入 Alpha Cognition 之前，Kalkofen 先生曾担任 Protagonist Therapeutics 的首席财务官，这是一家上市的临床阶段生物制药公司，他帮助指导公司实现强劲增长，并支持公司成功实施 SOX 404(b)。在职业生涯早期，Kalkofen 先生在 Symantec Corporation 和 West Coast Bancorp 担任首席财务官和高级财务领导职务，他在纳斯达克成功上市并将银行资产从 9000 万美元增长到 15 亿美元。</p>
</div><p>“Don’s track record of guiding biotechnology companies through transformational growth makes him the ideal financial leader for Genvor at this stage of our development,” said Chad Pawlak, Chief Executive Officer of Genvor. “His deep public company experience combined with his command of complex capital markets and partnership transactions positions him to support the structuring of future joint development agreements across both our agricultural and human health and wellness platforms.”</p>
<div class="lb-trans"><p>“Don 在指导生物科技公司经历转型增长方面的记录使他成为 Genvor 在这一发展阶段的理想财务领导，” Genvor 首席执行官 Chad Pawlak 表示。“他深厚的上市公司经验，加上对复杂资本市场和合作交易的掌控，使他能够支持未来在农业和人类健康与福祉平台上结构化的联合开发协议。”</p>
</div><p>“Genvor is at an exciting inflection point with a proprietary peptide platform, an expanding pipeline, and a clear path to growth across two complementary markets,” said Mr. Kalkofen. “Having helped guide biotechnology companies through similar transitions, I look forward to working alongside Chad and the team to strengthen Genvor’s financial foundation that will drive the company’s next phase of growth.”</p>
<div class="lb-trans"><p>“Genvor 正处于一个激动人心的转折点，拥有专有的肽平台、不断扩展的产品线，以及在两个互补市场上清晰的增长路径，” Kalkofen 先生表示。“我曾帮助生物科技公司经历类似的转型，期待与 Chad 和团队一起工作，强化 Genvor 的财务基础，推动公司的下一个增长阶段。”</p>
</div><p>Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.</p>
<div class="lb-trans"><p>Kalkofen 先生是一名注册会计师（非活跃），并持有华盛顿州立大学的会计学学士学位。</p>
</div><p><strong>About Genvor</strong></p>
<div class="lb-trans"><p><strong>关于 Genvor</strong></p>
</div><p>Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher™ platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Through its technology platforms and future partnerships, Genvor intends to advance a new era of natural, science-based innovation. For more information, visit www.genvor.com.</p>
<div class="lb-trans"><p>Genvor, Inc.（OTCQB: GNVR）是一家利用人工智能生成新型肽的生物科技公司，提供高性能解决方案，涵盖农业和人类健康。Genvor 依托其专有的 BioCypher™平台和专利肽，正在开发并打算商业化用于作物保护和植物健康的生物活性物质，以及面向消费者的肽解决方案，涵盖恢复、性能、抗衰老和日常健康。通过其技术平台和未来的合作伙伴关系，Genvor 旨在推动自然、基于科学的创新新时代。欲了解更多信息，请访问 www.genvor.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements.&#34; These statements include, but are not limited to, statements relating to the Company's operations. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Actual results may differ materially from those indicated by these forward-looking statements because of various important factors, including, without limitation, market conditions. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Genvor’s current plans, estimates, and beliefs. Genvor cannot guarantee future results, events, levels of activity, performance, or achievements. Genvor does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿中关于未来期望、计划和前景的声明，以及任何其他关于非历史事实事项的声明，可能构成 “前瞻性声明”。这些声明包括但不限于与公司运营相关的声明。词语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 和类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。本新闻稿中包含的前瞻性声明基于管理层当前的预期，并受到重大风险、不确定性和情况变化的影响。实际结果可能与这些前瞻性声明所指示的结果有实质性差异，原因包括但不限于市场条件等各种重要因素。所有这些声明仅在本新闻稿日期时有效。因此，前瞻性声明应仅被视为 Genvor 当前的计划、估计和信念。Genvor 无法保证未来的结果、事件、活动水平、表现或成就。Genvor 不承担并特别拒绝任何更新或修订前瞻性声明的义务，以反映新信息、未来事件或情况，或反映意外事件的发生，除非适用法律要求。</p>
</div><p><strong>Contacts:</strong> Carly Scaduto</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Carly Scaduto</p>
</div><p>carly@carlyscadutoconsulting.com</p>
<div class="lb-trans"><p>carly@carlyscadutoconsulting.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU5ETTJOaU0zTmpFME9UQTVJelV3TURFMU16RXdNUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyNDM2NiM3NjE0OTA5IzUwMDE1MzEwMQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDk2Nzc0ODktYzM4Zi00NGMzLTllMWItNDRiMGVhMDM5OTY4LTUwMDE1MzEwMS0yMDI2LTA1LTIxLWVu/tiny/Genvor-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/ZDk2Nzc0ODktYzM4Zi00NGMzLTllMWItNDRiMGVhMDM5OTY4LTUwMDE1MzEwMS0yMDI2LTA1LTIxLWVu/tiny/Genvor-Inc.png"/></p>

Genvor 公司任命 Donald Kalkofen 为首席财务官 | GNVR 股票新闻